section name header

Pronunciation

pa-MID-roe-nate

Classifications

Therapeutic Classification: bone resorption inhibitors

Pharmacologic Classification: biphosphonates, hypocalcemics

Indications

REMS


Action

  • Inhibits resorption of bone.
Therapeutic effects:
  • Decreased serum calcium.
  • Decreased skeletal destruction in multiple myeloma or breast cancer.
  • Decreased skeletal complications in Paget’s disease.

Pharmacokinetics

Absorption: IV administration results in complete bioavailability.

Distribution: Rapidly absorbed by bone. Reaches high concentrations in bone, liver, spleen, teeth, and tracheal cartilage. Approximately 50% of a dose is retained by bone and then slowly released.

Metabolism/Excretion: 50% is excreted unchanged in the urine.

Half-Life: Elimination half-life from plasma is biphasic—1st phase 1.6 hr, 2nd phase 27.2 hr. Elimination half-life from bone is 300 days.

Time/Action Profile

(effect on serum calcium)

ROUTEONSETPEAKDURATION
IV24 hr7 daysunknown





Contraind./Precautions

Contraindicated in:

Use Cautiously in:

Adv. Reactions/Side Effects

CV: arrhythmias, hypertension, syncope, tachycardia

EENT: blurred vision, conjunctivitis, eye pain/inflammation, rhinitis

Endo: hypothyroidism

F and E: hypocalcemia, hypokalemia, hypomagnesemia, hypophosphatemia, fluid overload

GI: nausea, abdominal pain, anorexia, constipation, vomiting

GU: nephrotoxicity

Hemat: leukopenia, anemia

Local: phlebitis at injection site

MS: muscle stiffness, pain, femur fractures, osteonecrosis (primarily of jaw)

Neuro: fatigue

Resp: rales

Misc: fever

Interactions

Drug-drug:

Route/Dosage

Hypercalcemia of Malignancy

Osteolytic Lesions from Multiple Myeloma

Osteolytic Lesions from Metastatic Breast Cancer

Paget’s Disease

Availability

(Generic available)

Assessment

Lab Test Considerations:

Implementation

IV Administration:

Patient/Family Teaching

Evaluation/Desired Outcomes